Pearce Sandra Timm, Liu Hong, Radhakrishnan Ishwar, Abdelrahim Maen, Safe Stephen, Jordan V Craig
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA.
Cancer Res. 2004 Apr 15;64(8):2889-97. doi: 10.1158/0008-5472.can-03-1770.
The polycyclic aromatic hydrocarbon 6-methyl-1,3,8-trichlorodibenzofuran (MCDF) is related to the industrial byproduct dioxin and is a weak agonist and partial antagonist at the aryl hydrocarbon receptor (AhR). Tamoxifen is used for the treatment and prevention of breast cancer and interferes with the interaction of estrogen with estrogen receptor alpha (ER). The combination of MCDF and tamoxifen lowered the effective dose of both drugs required to inhibit 7,12-dimethylbenz(a)anthracene-induced mammary tumor growth in rats and protected against the estrogenic effects of tamoxifen on the uterus in rats (A. McDougal et al., Cancer Res 2001;61:3902-7), pointing to the potential use of MCDF in breast cancer treatment. Potential AhR-ER cross-talk is evidenced by the antiestrogenic activity of MCDF and the degradative effect of MCDF on ER protein levels. Our studies confirmed that MCDF degraded the ER. MCDF displayed antiestrogenic activity at higher concentrations in MCF-7 human breast cancer cells, but MCDF alone (10(-6) M) stimulated the growth of MCF-7 cells. MCDF also activated an estrogen response element (ERE)-luciferase reporter and increased mRNA levels of the estrogen-responsive gene transforming growth factor (TGF)-alpha. The estrogenic effects of MCDF are ER dependent because they were blocked by the pure antiestrogen ICI 182,780. MCDF induced ER-coactivator interaction in glutathione S-transferase pull-down assays and the formation of an ER.ERE complex in gel mobility shift assays, further indicating that the estrogenic actions of MCDF are mediated by the ER. In addition, knockdown of the AhR with small interfering RNA did not affect MCDF-induced ERE-luciferase activity. Overall, these data support the conclusion that MCDF is a partial agonist at the ER. This study provides the first evidence for the direct interaction of the ER with MCDF and challenges the view that MCDF is simply an AhR-specific ligand.
多环芳烃6-甲基-1,3,8-三氯二苯并呋喃(MCDF)与工业副产品二噁英有关,是芳烃受体(AhR)的弱激动剂和部分拮抗剂。他莫昔芬用于治疗和预防乳腺癌,并干扰雌激素与雌激素受体α(ER)的相互作用。MCDF与他莫昔芬联合使用降低了抑制大鼠7,12-二甲基苯并(a)蒽诱导的乳腺肿瘤生长所需的两种药物的有效剂量,并防止了他莫昔芬对大鼠子宫的雌激素作用(A. McDougal等人,《癌症研究》2001年;61:3902 - 7),这表明MCDF在乳腺癌治疗中具有潜在用途。MCDF的抗雌激素活性以及MCDF对ER蛋白水平的降解作用证明了潜在的AhR - ER相互作用。我们的研究证实MCDF降解了ER。在MCF - 7人乳腺癌细胞中,较高浓度的MCDF表现出抗雌激素活性,但单独的MCDF(10^(-6) M)刺激了MCF - 7细胞的生长。MCDF还激活了雌激素反应元件(ERE)-荧光素酶报告基因,并增加了雌激素反应基因转化生长因子(TGF)-α的mRNA水平。MCDF的雌激素作用是ER依赖性的,因为它们被纯抗雌激素ICI 182,780阻断。在谷胱甘肽S - 转移酶下拉试验中,MCDF诱导了ER - 共激活因子相互作用,并且在凝胶迁移率变动试验中形成了ER.ERE复合物,进一步表明MCDF的雌激素作用是由ER介导的。此外,用小干扰RNA敲低AhR并不影响MCDF诱导的ERE - 荧光素酶活性。总体而言,这些数据支持MCDF是ER的部分激动剂这一结论。本研究首次提供了ER与MCDF直接相互作用的证据,并挑战了MCDF仅仅是AhR特异性配体的观点。